3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
9
Carcinoma, Non-Small-Cell Lung
8
Esophageal Squamous Cell Carcinoma
7
Stomach Neoplasms
4
Recurrence
4
Neoplasm Metastasis
4
Head and Neck Neoplasms
4
Lung Neoplasms
3
Colorectal Neoplasms
3
Advanced Solid Tumors
3
Advanced Solid Tumor
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Esophageal Neoplasms
2
Uterine Cervical Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
NSCLC
1
Multiple Pulmonary Nodules
1
Mid-low Rectal Cancer
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
pembrolizumab
2
Imatinib Mesylate
2
Cisplatin
2
Axitinib
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
tislelizumab
1
regorafenib
1
gallium 68 PSMA-11
1
avelumab
1
Tretinoin
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sunitinib
1
Radiation
1
Quality of Life
1
Patient Reported Outcome Measures
1
Nelfinavir
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Immunotherapy
1
GSK-3326595
1
Everolimus
1
Etoposide
1
Endoscopic Mucosal Resection
1
Drug Therapy
1
Doxorubicin
1
Cyclophosphamide
1
Bortezomib
1
Blood Specimen Collection
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Adenoid Cystic
×
tislelizumab
×
Clear all
NCT03287427
2023-02-15
MYPHISMO
Peter MacCallum Cancer Centre, Australia
Phase 1
Completed
27 enrolled